Shares ntawm Novavax Inc. poob ntau dua 6% hauv kev sib tham txuas ntxiv hnub Monday tom qab lub tuam txhab biotech tau tshaj tawm nws thawj lub hlis twg tau txais txiaj ntsig, tab sis tsis yog los ntawm ntau npaum li Wall Street xav tau, thiab nws qhov muag tau qis dua qhov kwv yees.
Novavax
NWS,
tau hais tias nws khwv tau $ 203 lab, lossis $ 2.56 ib feem, hauv peb lub hlis twg, hloov pauv los ntawm qhov poob ntawm $ 223 lab, lossis $ 3.05 ib feem, hauv lub xyoo dhau los.
Cov nyiaj tau los tau nce mus rau $ 704 lab, los ntawm $ 447 lab ib xyoos dhau los.
Cov kws tshuaj ntsuam xyuas los ntawm FactSet xav tias Novavax yuav tshaj tawm cov nyiaj tau los ntawm $ 2.69 ib feem ntawm kev muag khoom ntawm $ 845 lab.
Novavax tau hais tias nws tau "ua tiav" hauv kev tshaj tawm nws cov tshuaj tiv thaiv COVID-19 thoob ntiaj teb thiab nws tab tom taug kev los nthuav dav nws cov ntawv siv.
"Qhov tseem ceeb, raws li cov kev hloov pauv tshiab tau tshwm sim, peb tau ua tiav peb lub tswv yim los npaj los daws qhov chaw muaj zog thiab txuas ntxiv kev txhim kho dhau ntawm COVID-19 nrog peb cov neeg sib tw tiv thaiv COVID-19-influenza ua ke," Tus Thawj Saib Xyuas Haujlwm Stanley C. Erck tau hais hauv ib tsab ntawv. nqe lus.
Novavax tseem rov hais dua nws cov lus qhia txog nyiaj tau los ntawm 2022 ntawm $ 4 billion thiab $ 5 billion.
Lub tuam txhab tau xa daim ntawv thov kev tso cai siv xwm txheej ceev rau nws cov tshuaj tiv thaiv COVID-19, nrog rau US Food and Drug Administration pawg neeg tawm tswv yim tau teem caij ntsib rau Lub Rau Hli 7. Cov tshuaj tiv thaiv tau tso cai hauv ob peb lub tebchaws.
Tau qhov twg los: https://www.marketwatch.com/story/novavax-posts-first-quarterly-profit-but-misses-expectations-11652128156?siteid=yhoof2&yptr=yahoo